Clinical Trial Update: Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 efficacy trial of recombinant interleukin-21 for ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Recombinant Interleukin-21 (interleukin-21)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED